Avoiding the pharma blacklist

New Provisions creating a nationwide blacklist show the seriousness of the campaign against bribery and corruption. Here is what businesses should know about the new regulation

9 minute read June 24, 2014 at 12:29 PM
By
clpstaff and clp articles

The enhanced enforcement against corruption in the pharmaceutical and healthcare sector since June 2013 has led to intensified investigations into various multinational pharmaceutical companies in China.

Exclusive Content

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

  • Access to 3000+ essential documents, including key PRC laws translated into English
  • Newsletters with business-critical and sector-specific updates
  • Premium mobile access with timely analysis on China’s fast-changing market

Already a Subscriber? Log In Here

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)